Market revenue in 2024 | USD 28.6 million |
Market revenue in 2030 | USD 99.6 million |
Growth rate | 23.5% (CAGR from 2025 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 104.9% in 2024. Horizon Databook has segmented the Australia plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
Excellent research facilities, world-class researchers, and a firm but flexible regulatory framework have made Australia a powerhouse of pharmaceutical and biotechnology innovation. According to the data published by the Australian Trade and Investment Commission, Australia has become a hub for a thriving network of more than 470 biotechnology companies.
Significant presence of established pharmaceutical & biotechnology companies and extensive R&D initiatives being undertaken by them are expected to create high demand for plasmid DNA manufacturing solutions & systems in the country.
Manufacturing units in Australia are a combination of commercial enterprises like Luina Bio & Patheon and publicly sponsored organizations like the National Biologics Facility & Q-Gen. A partnership between the University of Queensland, University of Technology Sydney, and CSIRO has resulted in the establishment of National Biologics Facility.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account